Serological Changes of Monoclonal Antibody CAMA3C8 against Human Breast Cancer Cell Line
Author(s) -
Natarajan Muninathan,
K. Ponnazhagan,
T. S. Meghalatha
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i59a34284
Subject(s) - antigen , monoclonal antibody , breast cancer , serology , breast carcinoma , ca15 3 , glycoprotein , cancer , glycolipid , antibody , ca 15 3 , medicine , immunology , cancer research , biology , microbiology and biotechnology
Background: Tumor associated antigen are glycoproteins and glycolipids expressed on the surface or in the cytoplasm of tumor cells. The antigenic components are shed from the tumor cells into the tissue culture medium or blood or other human body fluids like human milk.
Objective: In the present study, investigate the serological assay of the antigen recognized by CAMA3C8 in patients with carcinoma of the breast.
Methods: The study is desgriptive cross section study.The study was divited into four groups based on the expression of tumor associated antigen.
Results: In breast cancer CAMA3C8 levels were significantly increased in stage 4 when compared with stage 1 breast cancer cell line.
Conclusion: In the present study, we conclude that significantly recognized CAMA3C8 defined antigens in breast cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom